Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas names new head of global development

This article was originally published in Scrip

Executive Summary

Astellas Pharma has named Eric Terhaerdt senior vice-president of global development operations. Mr Terhaerdt will be located at Astellas' headquarters for the Americas in Northbrook, Illinois, and will report to Dr Bernie Zeiher, executive vice-president of global development. In this role he will be responsible for establishing the global direction of the drug development operations of Astellas in the Netherlands and the US, and will work closely with Japanese development operations to ensure global operational effectiveness and efficiency.  Prior to joining Astellas, Mr Terhaerdt spent more than 20 years with AstraZeneca, serving in a variety of global leadership roles with increasing responsibility, in the areas of clinical research, clinical development, clinical quality, strategy and performance and scientific and technical evaluations. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel